310887-39-9 Usage
Molecular Weight
184.19 g/mol The molecular weight is the mass of one mole of the compound, calculated by adding the atomic weights of all the atoms in the molecular formula.
Structure
1H-Pyrrolo[2,3-b]pyridine-3-carbohydrazide has a fused ring system consisting of a pyrrolopyridine core and a carbohydrazide functional group.
Class
Pyrrolopyridines This compound belongs to the class of pyrrolopyridines, which are a group of organic compounds that contain a pyrrole ring fused to a pyridine ring.
Functional Group
Carbohydrazide The carbohydrazide functional group is present in this compound, which consists of a hydrazide group (-NHNH2) attached to a carbonyl group (C=O).
Applications
Pharmaceutical, Agrochemical, and Materials Science 1H-Pyrrolo[2,3-b]pyridine-3-carbohydrazide has potential applications in various fields, including the synthesis of organic compounds, pharmaceuticals, agrochemicals, and materials science.
Biological Activity
Studied for potential biological activities The compound has been studied for its potential biological activities, which could lead to the development of new drugs or therapies.
Unique Properties
Interesting target for further research and development The unique chemical structure and properties of 1H-Pyrrolo[2,3-b]pyridine-3-carbohydrazide make it an interesting target for further research and development in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 310887-39-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,1,0,8,8 and 7 respectively; the second part has 2 digits, 3 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 310887-39:
(8*3)+(7*1)+(6*0)+(5*8)+(4*8)+(3*7)+(2*3)+(1*9)=139
139 % 10 = 9
So 310887-39-9 is a valid CAS Registry Number.
310887-39-9Relevant articles and documents
HEPARANASE INHIBITORS AND USE THEREOF
-
Paragraph 0188, (2018/07/05)
The invention relates to functionalized quinazoline compounds, pharmaceutical compositions comprising such compounds, and the use of such compounds as heparanase inhibitors for the treatment of diseases or conditions related to heparanse activity.
The optimization of aminooxadiazoles as orally active inhibitors of Cdc7
Harrington, Paul E.,Bourbeau, Matthew P.,Fotsch, Christopher,Frohn, Michael,Pickrell, Alexander J.,Reichelt, Andreas,Sham, Kelvin,Siegmund, Aaron C.,Bailis, Julie M.,Bush, Tammy,Escobar, Sonia,Hickman, Dean,Heller, Scott,Hsieh, Faye,Orf, Jessica N.,Rong, Minqing,San Miguel, Tisha,Tan, Helming,Zalameda, Leeanne,Allen, John G.
, p. 6396 - 6400 (2013/11/19)
A series of aminooxadiazoles was optimized for inhibition of Cdc7. Early lead isoquinoline 1 suffered from modest cell potency (cellular IC50 = 0.71 μM measuring pMCM2), low selectivity against structurally related kinases, and high IV clearance in rats (CL = 18 L/h/kg). Extensive optimization resulted in azaindole 26 (Cdc7 IC50 = 1.1 nM, pMCM2 IC50 = 32 nM) that demonstrated robust lowering of pMCM2 in a mouse pharmacodynamic (PD) model when dosed orally. Modifications to improve the pharmacokinetic profile of this series were guided by trapping experiments with glutathione in rat hepatocytes.
OXADIAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS
-
Page/Page column 52, (2009/07/17)
Oxadiazole derivatives of formula (I) where ring A is a bicyclic or tricyclic system. Claimed compounds are active on nicotinic acetylcholine receptors (nAChRs), and are useful to treat neurological, psychiatric, and gastrointestinal disorders, as well as sepsis and obesity.
